Mai Capital Management Lineage Cell Therapeutics, Inc. Call Options Transaction History
Mai Capital Management
- $13 Billion
- Q1 2025
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding LCTX
# of Institutions
136Shares Held
103MCall Options Held
304KPut Options Held
0-
Broadwood Capital Inc New York, NY49.6MShares$50.1 Million2.94% of portfolio
-
Black Rock Inc. New York, NY9.56MShares$9.66 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA8.48MShares$8.57 Million0.0% of portfolio
-
Defender Capital, Llc.6.79MShares$6.85 Million2.42% of portfolio
-
Raffles Associates LP New York, NY5.64MShares$5.7 Million3.45% of portfolio
About Lineage Cell Therapeutics, Inc.
- Ticker LCTX
- Exchange NYSE
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 169,755,008
- Market Cap $171M
- Description
- Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, develops novel cell therapies for the treatment of degenerative diseases in the United States and internationally. The company develops OpRegen, a retinal pigment epithelium cell replacement therapy, which is in Phase I/IIa clinical trial for the treatment of the dry age-re...